Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High – Should You Buy?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $54.24 and last traded at $53.60, with a volume of 160513 shares trading hands. The stock had previously closed at $50.65.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

The company has a market cap of $2.01 billion, a PE ratio of -13.31 and a beta of 1.04. The firm’s fifty day moving average is $44.35 and its 200 day moving average is $34.25. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth $61,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth $114,000. FMR LLC grew its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after buying an additional 3,379 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.